Skip to main content
Decorative image of the AMR Learning Lounge

Study Shows FDA-Approved TB Regimen May Not Work Against the Deadliest Form of TB Due to Multidrug-Resistant Strains

SUMMARY

In a recent study, Johns Hopkins researchers found that a 2019 FDA-approved antibiotic regimen for multi-drug resistant (MDR) strains of pulmonary TB may not work in cases of TB meningitis. Results showed that while the (BPaL) regimen may work well for MDR TB strains in the lungs, it may be less effective than a standard TB regimen in cases of TB meningitis. According to the study, this is likely due to restricted penetration of bedaquiline and linezolid into the brain to help treat these infections.

FEATURED EXPERT

Sanjay Jain, MBBS, MD, Director of Johns Hopkins Medicine Center for Infection and Inflammation Imaging Research


GET STARTED

Read the complete Johns Hopkins Medicine Newsroom article.

Read time: 4 minutes


We want to hear from you!

Your feedback helps us continue to provide resources and content specific to your needs.


U.S. bioMérieux Solutions

Global Solution

VIDAS® TB-IGRA

Available on the VIDAS® 3 immunoanalyzer, VIDAS® TB-IGRA is a whole-blood test for the diagnosis of Mycobacterium tuberculosis infection.

U.S. bioMérieux Solutions

US SOlution

VIDAS® 3

With its advanced immunoassay technology and optimized testing protocols, the fully automated VIDAS® 3 benchtop immunoanalyzer empowers your lab with confidence, offering the precise results you need, when you need them.

PUBLISHED BY

Johns Hopkins Medicine Newsroom
January 27, 2023


SHARE THIS ARTICLE: